首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學細胞療法基因療法

市場調查報告書

商品編碼

2055349

細胞和基因療法市場：按治療方法、應用、最終用戶和地區分類

Cell and Gene Therapy Market, By Therapy Type, By Application, By End User, By Geography

出版日期: 2026年03月31日 | 出版商:

Coherent Market Insights | 英文 153 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，細胞和基因治療市場規模將達到447.5億美元，2033年將達到1,485.8億美元。預計從2026年到2033年，該市場將以18.7%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	447.5億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	18.70%	2033年市場規模預測：	1485.8億美元

細胞療法是治療方法，它將新的細胞引入患者體內，以治療疾病、促進生長、替換或修復受損組織。細胞療法中使用的細胞類型多種多樣，包括幹細胞、淋巴細胞和樹突狀細胞。細胞療法可以使用取自患者本身（自體細胞）或來自捐贈者的（異體細胞）細胞。許多細胞療法利用經過基因重編程的成人細胞，使其分化成患者體內的各種細胞類型。這項技術有望實現無限量地生成治療所需的任何類型的人體細胞。

基因療法旨在透過修改或導入基因，以治療、預防甚至治癒疾病。基因療法的例子包括用功能正常的基因拷貝取代致病突變基因，或將新的正常基因拷貝導入體內。

市場動態

細胞和基因療法在現代醫療保健中發揮著至關重要的作用，因為它提供了可用於基因調控、細胞間相互作用、再生能力和重塑的概念和技術。因此，主要市場參與者正致力於採取各種成長策略，包括推出產品和平台，預計這將推動預測期內的市場成長。例如，2023年4月4日，全球醫療保健公司AmerisSourceBergen宣布推出細胞和基因療法（CGT）整合中心，該系統可與生物製藥公司和醫療保健提供者的平台整合。該系統促進即時數據交換，並支援從治療方案開發到患者治療進展的服務協調。

此外，CGT整合中心基於AmerisSourceBergen創新的客戶關係管理（CRM）系統構建，獨立於任何平台，旨在透過為醫生和患者服務團隊提供整個治療方法開發和實施過程的可視性，簡化就醫流程。透過平台整合，CGT整合中心可實現以下功能：

這將加快理賠審核流程，使醫生在輸入病患登記資料後幾乎可以立即收到有關病患保險範圍的決定。
為了簡化患者預約流程，我們將使醫生和護理經理能夠獲取有關治療方法進展和交通的即時資訊。
我們會將情況的任何變化（例如抵達日期的延遲）通知個案經理，以便我們能夠提前聯繫患者和看護者，以便我們能夠根據需要修改已安排的治療相關活動和住院計劃。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於以下參數分析了全球細胞和基因治療市場的主要參與者：公司亮點、產品系列、主要亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球細胞和基因治療市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球細胞和基因治療市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

Novartis International AG
Pfizer, Inc.
Sanofi SA
Amgen, Inc.
Regeneron Pharmaceuticals, Inc.
Bluebird Bio, Inc.（Celgene Corporation）
Biogen Inc.
uniQure NV
JCR Pharmaceuticals Co. Ltd.
Gene Biotherapeutics
Kolon TissueGene, Inc.
Horama SA
MeiraGTx Limited
Gilead Sciences, Inc.
Organogenesis, Inc.
Orchard Therapeutics Plc.
Freeline Therapeutics Ltd.
Bristol-Myers Squibb Company
PTC Therapeutics, Inc.
Spark Therapeutics, Inc.
Biomarin Pharmaceutical Inc.

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI2475

Cell And Gene Therapy Market is estimated to be valued at USD 44.75 Bn in 2026 and is expected to reach USD 148.58 Bn by 2033, growing at a compound annual growth rate (CAGR) of 18.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 44.75 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	18.70%	2033 Value Projection:	USD 148.58 Bn

Cell therapy is the introduction of new cells into a patient's body to grow, replace, or repair damaged tissue in order to treat a disease. A variety of different types of cells can be used in cell therapy, including stem cells, lymphocytes, and dendritic cells. Cell therapies can use cells from the patient's own body (autologous) or from a donor (allogenic). Many cell therapies use adult cells that have been genetically reprogrammed and capable of becoming one of many types of cells inside a patient's body. This technology may enable the development of unlimited types of specific human cells needed for therapeutic purposes.

Gene therapy seeks to modify or introduce genes into a patient's body with the goal of treating, preventing, or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy or introducing a new, correct copy of a gene into the body.

Market Dynamics

Cell and gene therapy plays a major role in modern healthcare, as it provides concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling. Thus, key market players are focused on adopting various growth strategies such as product/platform launches and others, which in turn is expected to fuel the market growth over the forecast period. For instance, on April 4, 2023, AmerisourceBergen, a global healthcare company, announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.

Furthermore, The CGT Integration Hub, which is platform-agnostic and powered by AmerisourceBergen's innovative customer relationship management (CRM) system, aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can

Speed up the benefits investigation process so that after physicians enter patient enrollment data, they can get a decision on the patient's coverage almost immediately.
To facilitate patient scheduling, give doctors and care managers real-time access to information on the status of the development of the therapy and transportation.
Inform case managers of any status changes, such as postponed arrival dates, so they can contact patients and caregivers in advance to amend any scheduled treatment-related activities or stays, as necessary.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global cell and gene therapy market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., Bluebird Bio, Inc. (Celgene Corporation) , Biogen Inc., uniQure N.V., JCR Pharmaceuticals Co. Ltd., Gene Biotherapeutics, Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Organogenesis, Inc., Orchard Therapeutics Plc., Freeline Therapeutics Ltd. , Bristol-Myers Squibb Company, PTC Therapeutics, Inc., Spark Therapeutics, Inc. and Biomarin Pharmaceutical Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy market.

Market Segmentation

Global Cell and Gene Therapy Market, By Therapy Type (Revenue, USD Bn, 2021 - 2033)
Cell Therapy
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
Gene Therapy
- Germline Gene Therapy
- Somatic Gene Therapy
Global Cell and Gene Therapy Market, By Application (Revenue, USD Bn, 2021 - 2033)
Dermatology
Musculoskeletal
Oncology
Immunology
Cardiology & Neurology
Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
Global Cell and Gene Therapy Market, By End user (Revenue, USD Bn, 2021 - 2033)
Hospitals
Clinics
Others (Research Institutes, Academic Institutes, etc.)
Global Cell and Gene Therapy Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players
Novartis International AG
Pfizer, Inc.
Sanofi S.A.
Amgen, Inc.
Regeneron Pharmaceuticals, Inc.
Bluebird Bio, Inc. (Celgene Corporation)
Biogen Inc.
uniQure N.V.
JCR Pharmaceuticals Co. Ltd.
Gene Biotherapeutics
Kolon TissueGene, Inc.
Horama S.A.
MeiraGTx Limited
Gilead Sciences, Inc.
Organogenesis, Inc.
Orchard Therapeutics Plc.
Freeline Therapeutics Ltd.
Bristol-Myers Squibb Company
PTC Therapeutics, Inc.
Spark Therapeutics, Inc.
Biomarin Pharmaceutical Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Application
- Market Snapshot, By End user
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Technological Advancements
Manufacturer Revenue
Pipeline Analysis

4. Global Cell and Gene Therapy Market, By Therapy Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Segment Trends
  - Stem Cells
  - T Cells
  - Dendritic Cells
  - NK Cells
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Segment Trends
  - Germline Gene Therapy
  - Somatic Gene Therapy

5. Global Cell and Gene Therapy Market, By Application, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Dermatology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Segment Trends
Musculoskeletal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Segment Trends
Immunology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Segment Trends
Cardiology & Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Segment Trends
Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Segment Trends

6. Global Cell and Gene Therapy Market, By End user, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others (Research Institutes, Academic Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Cell and Gene Therapy Market, By Region, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amgen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bluebird Bio, Inc. (Celgene Corporation)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
uniQure N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
JCR Pharmaceuticals Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gene Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kolon TissueGene, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Horama S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
MeiraGTx Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Organogenesis, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Orchard Therapeutics Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Freeline Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PTC Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Spark Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biomarin Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies